Melane Sampson, Author at BioTuesdays

Developments

CellAegis completes enrollment in heart attack study with autoRIC

Closely-held CellAegis Devices completed enrollment in an investigator sponsored study (FIRST) to evaluate the clinical and economic benefits of remote ischemic conditioning (RIC) therapy in the treatment of patients...

September 11, 2018

Feature

Actinium Pharma developing targeted conditioning for bone marrow transplant

By Len Zehr Actinium Pharmaceuticals (NYSE American:ATNM) intends to improve bone marrow transplants (BMT) access and patient outcomes and treat cancers with high unmet medical needs by combining the precision of...

September 11, 2018

Developments

Ortho RTi in pact with CMO to manufacture cGMP quantities of Ortho-R

Ortho Regenerative Technologies (CSE:ORTH) entered into an agreement with a leading contract manufacturing organization operating within the global biopharmaceutical industry to begin work on providing Ortho RTi with...

September 6, 2018

Markets

Leerink resumes coverage of ObsEva at OP; PT $25

Leerink resumed coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and $25 price target. The stock finished at $13 on August 14. “We believe that at current levels the stock does not fully reflect the...

August 15, 2018

Feature

Pharnext platform taps genomic data, AI for new combination medicines

By Melane Sampson A new drug discovery paradigm, PLEOTHERAPY, developed by Pharnext SA (FR0011191287-ALPHA) is based on big genomic data, artificial intelligence, and rigorous experimental analysis that involves...

August 14, 2018

Markets

Ladenburg cuts Scynexis PT to $6 from $10

Ladenburg Thalmann lowered its price target for Scynexis (NASDAQ:SCNX) to $6 from $10, citing another delay in development of an IV formulation of ibrexafungerp. The stock closed at $1.39 on August 10. “As successful as...

August 13, 2018

Markets

Stifel cuts Corindus Vascular Robotics to hold; PT $1

Stifel downgraded Corindus Vascular Robotics (NYSE AMER:CVRS) to “hold” from “buy” and slashed its price target to $1 from $3 after “disappointing” first half results and now-lower 2018-2020 sales projects. Shares of...

August 8, 2018

Markets

Echelon cuts Arbutus Biopharma to hold; maintains PT at $12.25

Echelon Wealth Partners downgraded Arbutus Biopharma (NASDAQ:ABUS) to “hold” from “speculative buy” with a price target of $12.25 based on valuation. The stock was quoted at $11.40 at midday on July 27. Analyst Doug Loe...

July 27, 2018

Developments

Respinova wins Chiesi Spain and Richi Entrepreneurs second call

Israel-based Respinova has won the second grant offered by Chiesi Spain and Richi Entrepreneurs to promote an innovative project that directly impacts treatment and quality of life of patients with chronic obstructive...

July 24, 2018

Markets

HCW cuts Mersana Therapeutics PT to $16 from $33

H.C. Wainwright slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $16 from $33 after the company disclosed a partial clinical hold on its lead clinical program targeting HER2 expressing cancers. The...

July 20, 2018

Author - Melane Sampson

CellAegis completes enrollment in heart attack study with autoRIC

Actinium Pharma developing targeted conditioning for bone marrow transplant

Ortho RTi in pact with CMO to manufacture cGMP quantities of Ortho-R

Leerink resumes coverage of ObsEva at OP; PT $25

Pharnext platform taps genomic data, AI for new combination medicines

Ladenburg cuts Scynexis PT to $6 from $10

Stifel cuts Corindus Vascular Robotics to hold; PT $1

Echelon cuts Arbutus Biopharma to hold; maintains PT at $12.25

Respinova wins Chiesi Spain and Richi Entrepreneurs second call

HCW cuts Mersana Therapeutics PT to $16 from $33

General

More